| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV P Tebas, D Stein, WW Tang, I Frank, SQ Wang, G Lee, SK Spratt, ... New England Journal of Medicine 370 (10), 901-910, 2014 | 1737 | 2014 |
| Maraviroc for previously treated patients with R5 HIV-1 infection RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ... New England Journal of Medicine 359 (14), 1429-1441, 2008 | 913 | 2008 |
| Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy P Tebas, WG Powderly, S Claxton, D Marin, W Tantisiriwat, SL Teitelbaum, ... Aids 14 (4), F63-F67, 2000 | 703 | 2000 |
| Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz … GA McComsey, D Kitch, ES Daar, C Tierney, NC Jahed, P Tebas, L Myers, ... Journal of Infectious Diseases 203 (12), 1791-1801, 2011 | 596 | 2011 |
| Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1 S Naggie, C Cooper, M Saag, K Workowski, P Ruane, WJ Towner, ... New England Journal of Medicine 373 (8), 705-713, 2015 | 570 | 2015 |
| Bone disease in HIV infection: a practical review and recommendations for HIV care providers GA McComsey, P Tebas, E Shane, MT Yin, ET Overton, JS Huang, ... Clinical infectious diseases 51 (8), 937-946, 2010 | 487 | 2010 |
| Prevalence and predictive value of intermittent viremia with combination HIV therapy DV Havlir, R Bassett, D Levitan, P Gilbert, P Tebas, AC Collier, MS Hirsch, ... Jama 286 (2), 171-179, 2001 | 479 | 2001 |
| Effect of HIV antibody VRC01 on viral rebound after treatment interruption KJ Bar, MC Sneller, LJ Harrison, JS Justement, ET Overton, ME Petrone, ... New England Journal of Medicine 375 (21), 2037-2050, 2016 | 473 | 2016 |
| Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection G Fätkenheuer, M Nelson, A Lazzarin, I Konourina, AIM Hoepelman, ... New England Journal of Medicine 359 (14), 1442-1455, 2008 | 427 | 2008 |
| Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study A Castagna, F Maggiolo, G Penco, D Wright, A Mills, R Grossberg, ... The Journal of infectious diseases 210 (3), 354-362, 2014 | 420 | 2014 |
| Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents R Bedimo, NM Maalouf, S Zhang, H Drechsler, P Tebas Aids 26 (7), 825-831, 2012 | 401 | 2012 |
| Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus—infected individuals K Mondy, K Yarasheski, WG Powderly, M Whyte, S Claxton, D DeMarco, ... Clinical Infectious Diseases 36 (4), 482-490, 2003 | 379 | 2003 |
| Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind … J Gallant, A Lazzarin, A Mills, C Orkin, D Podzamczer, P Tebas, PM Girard, ... The Lancet 390 (10107), 2063-2072, 2017 | 377 | 2017 |
| Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy DV Havlir, IC Marschner, MS Hirsch, AC Collier, P Tebas, RL Bassett, ... New England Journal of Medicine 339 (18), 1261-1268, 1998 | 354 | 1998 |
| Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens DV Havlir, NS Hellmann, CJ Petropoulos, JM Whitcomb, AC Collier, ... Jama 283 (2), 229-234, 2000 | 349 | 2000 |
| Safety and immunogenicity of an anti–Zika virus DNA vaccine P Tebas, CC Roberts, K Muthumani, EL Reuschel, SB Kudchodkar, ... New England Journal of Medicine 385 (12), e35, 2021 | 305 | 2021 |
| DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations C Hoffmann, N Minkah, J Leipzig, G Wang, MQ Arens, P Tebas, ... Nucleic acids research 35 (13), e91, 2007 | 290 | 2007 |
| HIV-protease inhibitors impair vitamin D bioactivation to 1, 25-dihydroxyvitamin D M Cozzolino, M Vidal, MV Arcidiacono, P Tebas, KE Yarasheski, ... Aids 17 (4), 513-520, 2003 | 283 | 2003 |
| A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia V Amorosa, M Synnestvedt, R Gross, H Friedman, RR MacGregor, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 39 (5), 557-561, 2005 | 258 | 2005 |
| Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides MP Dube, RA Parker, P Tebas, SK Grinspoon, RA Zackin, GK Robbins, ... Aids 19 (16), 1807-1818, 2005 | 247 | 2005 |
Carl JuneUniversity of Pennsylvania在 upenn.edu 的电子邮件经过验证
